Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 27, 2023

BUY
$132.51 - $164.9 $3.19 Million - $3.97 Million
24,099 New
24,099 $3.25 Million
Q4 2022

Feb 15, 2023

SELL
$138.31 - $165.87 $414,653 - $497,278
-2,998 Reduced 11.82%
22,369 $3.62 Million
Q3 2022

Nov 07, 2022

BUY
$134.21 - $153.93 $2.13 Million - $2.44 Million
15,853 Added 166.63%
25,367 $3.4 Million
Q2 2022

Aug 09, 2022

BUY
$137.62 - $174.96 $1.31 Million - $1.66 Million
9,514 New
9,514 $1.46 Million
Q1 2022

May 17, 2022

SELL
$131.98 - $163.75 $2.19 Million - $2.72 Million
-16,586 Closed
0 $0
Q4 2021

Feb 17, 2022

BUY
$107.43 - $135.93 $598,170 - $756,858
5,568 Added 50.54%
16,586 $2.25 Million
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $564,452 - $640,737
5,305 Added 92.86%
11,018 $1.19 Million
Q2 2021

Sep 17, 2021

BUY
$105.21 - $117.21 $601,064 - $669,620
5,713 New
5,713 $644,000
Q2 2020

Aug 07, 2020

SELL
$73.37 - $98.18 $2.89 Million - $3.86 Million
-39,323 Closed
0 $0
Q4 2019

Feb 04, 2020

BUY
$72.13 - $90.25 $1.87 Million - $2.34 Million
25,942 Added 193.87%
39,323 $3.48 Million
Q3 2019

Nov 20, 2019

BUY
$62.98 - $75.72 $842,735 - $1.01 Million
13,381 New
13,381 $1.01 Million
Q2 2018

Jul 30, 2018

SELL
$89.78 - $106.23 $1.6 Million - $1.89 Million
-17,809 Closed
0 $0
Q2 2018

Jul 30, 2018

BUY
$89.78 - $106.23 $1.01 Million - $1.2 Million
11,305 Added 173.82%
17,809 $1.65 Million
Q1 2018

May 14, 2018

SELL
$92.01 - $123.21 $976,502 - $1.31 Million
-10,613 Reduced 62.0%
6,504 $616,000
Q4 2017

Feb 09, 2018

BUY
$89.56 - $98.21 $465,264 - $510,200
5,195 Added 43.57%
17,117 $1.66 Million
Q3 2017

Nov 15, 2017

BUY
$69.85 - $89.22 $832,751 - $1.06 Million
11,922
11,922 $1,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $355B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.